Benzinga | Apr 27, 2021 07:31AM EDT

Brickell Biotech Completes Patient Enrollment In US Phase 3 Pivotal Cardigan I Study Of Sofpironium Bromide Gel, 15% For The Treatment Of Primary Axillary Hyperhidrosis

Brickell Biotech, Inc. ("Brickell" or the "Company") (NASDAQ:BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, today announced completion of patient enrollment in the Phase 3 pivotal Cardigan I study and that the Cardigan II study has surpassed 50% enrollment. Both studies are evaluating sofpironium bromide gel, 15% in patients with primary axillary (underarm) hyperhidrosis.